Stay updated on Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study completion date for the clinical trial of Nivolumab combined with Ipilimumab followed by Nivolumab monotherapy as first-line treatment for patients with advanced Melanoma (CheckMate 401). This change may reflect a recent development in the research progress or timeline of the study related to medical and healthcare publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:22.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed information about eligibility criteria for clinical trial participants, including specific health conditions and prior treatments required for inclusion. It now also includes a link for more information on BMS clinical trial participation.
    Difference
    17%
    Check dated 2024-05-22T21:30:57.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:57:11.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.